Remove 2012 Remove Documentation Remove Insurance Remove Pharmaceutical Companies
article thumbnail

The 20 Key Moments in the 340B Program's 30-Year History

Omnicell

In a manual for hemophilia treatment centers, the agency states it is concerned that providers would have no reason to participate in 340B if insurers take the benefit of 340B savings from them. 2012: Following the recommendation of the GAO, HRSA began conducting audits of 340B covered entities and later expands audits to drug manufacturers.